İbRahim Ethem Geçim

İbRahim Ethem Geçim

Auto-generated profile, based on publicly available information

İbRahim Ethem Geçim

Department of Surgery, Ankara University Faculty of Medicine, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2022 in Molecular Imaging and Radionuclide Therapy
Verified
Journal Article
Open access
CSCigdem Soydal
Cigdem Soydal
MAMine Araz
Mine Araz
MDMustafa Durmaz
Mustafa Durmaz
EÖElgin Özkan
Elgin Özkan
BEBerrin İmge Ergüder
Berrin İmge Ergüder
IGİbrahim Ethem Geçim
İbrahim Ethem Geçim
Objectives: To analyze the change in circulating angiogenic factor levels after transarterial radioembolization (TARE) for colorectal cancer liver metastases (CRCLMs) and its prognostic significance. Methods: Blood samples immediately before TARE and on 1 day, 1 week and 6 weeks after were collected for angiogenic factor analysis in 23 patients. Results: Patients with elevated serum basic fibroblast growth factor and platelet-derived growth factor levels in the 1st week and vascular endothelial growth factor (VEGF) levels in the 6th week after TARE had significantly shorter median overall survival (OS) times. Conclusion: Some early increases in serum angiogenic factor levels and in serum VEGF in the eh week after TARE for CRCLMs are related to short OS and progression-free survival.

15 December 2022 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
HCHaydar Celasin
Haydar Celasin
MTMurat Toruner
Murat Toruner
SASevda Aghayeva
Sevda Aghayeva
NBNuru Bayramov
Nuru Bayramov
AVArmen Vardanyan
Armen Vardanyan
IGİbRahim Ethem Geçim
İbRahim Ethem Geçim
Background: Since December 2019, the COVID-19 pandemic has created an increasing challenge in managing inflammatory bowel dis- ease patients both medically and surgically. Although several international and national medical/surgical associations published guide- lines in this area, there is still a huge difference between daily practices and these guidelines, especially depending on regional practices and governmental policies. Therefore, we aimed to investigate and define gastroenterologists’ and surgeons’ fear of COVID-19 and how they have managed inflammatory bowel disease patients during this pandemic in the Black Sea region. Methods: A 20-question survey was administered to 70 gastroenterology specialists and 80 general surgeons who are mainly focused on the management of inflammatory bowel disease in 5 countries in the Black Sea region. Results: The majority of respondents (81.3%) mentioned that they have concerns that their inflammatory bowel disease patients were at risk of contracting COVID-19. In addition, the majority of respondents (80.3%) believed that inflammatory bowel disease itself, inde- pendent of medications, might increase the risk of contracting COVID-19. The majority of gastroenterologists told that they did not stop inflammatory bowel disease medications due to the COVID-19 pandemic unless patients had COVID-19 disease. Surgeons overwhelm- ingly reached a consensus on how to test patients for COVID-19 perioperatively and came to a conclusion on which of the patients can- not wait to be operated. Both gastroenterologists and general surgeons, usually have similar perceptions. Conclusion: Despite the increasing number of definitive studies, it seems that there are still regional differences in the perception of COVID-19 and inflammatory bowel disease patient care during the pandemic. Cite this article as: Celasin H, Törüner M, Aghayeva S, et al. Perception of COVID-19 pandemic among IBD clinicians and IBD surgeons in Black Sea region: A cross-sectional questionnaire study. Turk J Gastroenterol. 2022;33(12):1004-1011.